A compound of formula (I), a pharmaceutically acceptable salt or ester or other derivative thereof:
R1 is optionally substituted cycloalkyl or optionally substituted saturated heterocyclic group. R2 is optionally substituted aryl or optionally substituted heteroaryl. A is methylene, carbonyl or sulfonyl. B is a single bond, alkylene or alkenylene. D is oxygen or sulfur. G is alkylene or alkenylene. L is —N(R3)— or —C(R4)(R5)—. R3 is optionally substituted aryl or optionally substituted heteroaryl. R4 is H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted saturated heterocyclic group. R5 is alkyl optionally substituted with amino, amino, optionally substituted acylamino, OH, optionally substituted hydroxyalkyl, alkoxy or —CO—R6. R6 is alkyl, alkoxy or amine residue. R4 together with R5 forms a cycloalkane ring, cycloalkene ring, or saturated heterocyclic ring. R7 is alkyl. Z is two hydrogens or oxygen. n is 0. 1 or 2. These compounds have selective antagonistic activity against the NK2 receptor.
化合物的公式(I),其药物可接受的盐或酯或其他衍
生物:R1是可选取代的环烷基或可选取代的饱和杂环基。R2是可选取代的芳基或可选取代的杂环芳基。A是亚甲基,羰基或磺酰基。B是单键,烷基或烯基。D是氧或
硫。G是烷基或烯基。L是-N(R3)-或-C(R4)(R5)-。R3是可选取代的芳基或可选取代的杂环芳基。R4是H,可选取代的芳基,可选取代的杂环芳基,可选取代的环烷基或可选取代的饱和杂环基。R5是烷基,可选取代的
氨基,
氨基,可选取代的酰胺基,OH,可选取代的羟基烷基,烷氧基或-CO-R6。R6是烷基,烷氧基或胺基残基。R4与R5一起形成环烷基环,环烯基环或饱和杂环环。R7是烷基。Z是两个氢或氧。n为0.1或2。这些化合物具有对NK2受体的选择性拮抗活性。